Immunomedics Veltuzumab showed efficacy in ITP
Veltuzumab, a humanized anti-CD20 antibody was constructed using the same human donor frameworks as epratuzumab. The results demonstrated that two doses of veltuzumab produced an overall objective response
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.